This review does not present new data for those who are familiar with the use of antifibrinolytics in the perioperative setting. It constitutes, however, a very useful summary of the current situation regarding these drugs. In practice, tranexamic acid is the only antifibrinolytic available in a majority of centers. While it appears to be safe, more studies will be required to confirm the absence of side effects such as convulsions (at higher doses) or thromboembolic events.
– Jean-François Hardy